These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 16007902)
1. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Tefferi A; Gilliland DG Mayo Clin Proc; 2005 Jul; 80(7):947-58. PubMed ID: 16007902 [TBL] [Abstract][Full Text] [Related]
2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
3. JAK2 in myeloproliferative disorders is not just another kinase. Tefferi A; Gilliland DG Cell Cycle; 2005 Aug; 4(8):1053-6. PubMed ID: 15970705 [TBL] [Abstract][Full Text] [Related]
4. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609 [TBL] [Abstract][Full Text] [Related]
5. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation]. Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592 [TBL] [Abstract][Full Text] [Related]
6. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512 [TBL] [Abstract][Full Text] [Related]
7. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Tefferi A Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067 [TBL] [Abstract][Full Text] [Related]
8. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288 [TBL] [Abstract][Full Text] [Related]
9. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Pikman Y; Levine RL Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464 [TBL] [Abstract][Full Text] [Related]
10. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders. Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952 [TBL] [Abstract][Full Text] [Related]
11. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Vainchenker W; Constantinescu SN Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380 [TBL] [Abstract][Full Text] [Related]
12. The V617F JAK2 mutation and the myeloproliferative disorders. Percy MJ; McMullin MF Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006 [TBL] [Abstract][Full Text] [Related]
13. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR; Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101 [TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Nelson ME; Steensma DP Leuk Lymphoma; 2006 Feb; 47(2):177-94. PubMed ID: 16321848 [TBL] [Abstract][Full Text] [Related]
15. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Valentino L; Pierre J Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581 [TBL] [Abstract][Full Text] [Related]
16. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610 [TBL] [Abstract][Full Text] [Related]
17. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Tefferi A; Barbui T Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503 [TBL] [Abstract][Full Text] [Related]
18. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187 [TBL] [Abstract][Full Text] [Related]
19. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459 [TBL] [Abstract][Full Text] [Related]
20. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Tefferi A; Gilliland G Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]